• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by agilon health inc.

    8/29/25 11:00:27 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $AGL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    agilon health, inc.

    (Name of Issuer)


    Common stock, par value $0.01

    (Title of Class of Securities)


    00857U107

    (CUSIP Number)


    08/22/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00857U107


    1Names of Reporting Persons

    North Peak Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    18,276,374.00
    7Sole Dispositive Power

    3,260,305.00
    8Shared Dispositive Power

    18,276,374.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    21,536,679.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 1,247,465 shares of Common stock, par value $0.01 ("Common Stock") of aglion health, inc (the "Issuer") held directly by North Peak Capital Partners, LP, (2) 10,585,833 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 5,564,235 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 878,841 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 414,423,149 Common Stock outstanding as of July 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025 filed with the U.S. Securities and Exchange Commission (the "Commission") on August 4, 2025.


    SCHEDULE 13G

    CUSIP No.
    00857U107


    1Names of Reporting Persons

    North Peak Capital GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    18,276,374.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    18,276,374.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,276,374.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 1,247,465 shares of Common Stock held directly by North Peak Capital Partners, LP, (2) 10,585,833 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 5,564,235 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 878,841 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 414,423,149 Common Stock of the Issuer outstanding as of July 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 4, 2025.


    SCHEDULE 13G

    CUSIP No.
    00857U107


    1Names of Reporting Persons

    North Peak Capital Partners, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,247,465.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,247,465.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,247,465.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.30 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 414,423,149 Common Stock of the Issuer outstanding as of July 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 4, 2025.


    SCHEDULE 13G

    CUSIP No.
    00857U107


    1Names of Reporting Persons

    North Peak Capital Partners II, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,585,833.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,585,833.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,585,833.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.6 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 414,423,149 Common Stock of the Issuer outstanding as of July 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 4, 2025.


    SCHEDULE 13G

    CUSIP No.
    00857U107


    1Names of Reporting Persons

    North Peak Capital Alpha Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,564,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,564,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,564,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 414,423,149 Common Stock of the Issuer outstanding as of July 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 4, 2025.


    SCHEDULE 13G

    CUSIP No.
    00857U107


    1Names of Reporting Persons

    North Peak Capital Ultra Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    878,841.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    878,841.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    878,841.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The figure in Item 11 is based upon 414,423,149 Common Stock of the Issuer outstanding as of July 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 4, 2025.


    SCHEDULE 13G

    CUSIP No.
    00857U107


    1Names of Reporting Persons

    Michael Kevin Kahan
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    18,276,374.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    18,276,374.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,276,374.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 1,247,465 shares of Common Stock held directly by North Peak Capital Partners, LP, (2) 10,585,833 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 5,564,235 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 878,841 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 414,423,149 Common Stock of the Issuer outstanding as of July 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 4, 2025.


    SCHEDULE 13G

    CUSIP No.
    00857U107


    1Names of Reporting Persons

    Jeremy Steven Kahan
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    18,276,374.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    18,276,374.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,276,374.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    HC, CO

    Comment for Type of Reporting Person:  The figures in Items 6, 8, and 9 include (1) 1,247,465 shares of Common Stock held directly by North Peak Capital Partners, LP, (2) 10,585,833 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 5,564,235 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 878,841 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 414,423,149 Common Stock of the Issuer outstanding as of July 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 4, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    agilon health, inc.
    (b)Address of issuer's principal executive offices:

    6210 E HWY 290, Suite 450, Austin, TX, 78723
    Item 2. 
    (a)Name of person filing:

    This statement is jointly filed by and on behalf of each of North Peak Capital Management, LLC, a Delaware limited liability company ("North Peak Management"), North Peak Capital GP, LLC, a Delaware limited liability company ("North Peak GP"), North Peak Capital Partners, LP, a Delaware limited partnership ("Fund I"), North Peak Capital Partners II, LP, a Delaware limited partnership ("Fund II"), North Peak Capital Alpha Fund, LP, a Delaware limited partnership ("Alpha Fund"), North Peak Capital Ultra Fund, LP, a Delaware limited partnership ("Ultra Fund"), Jeremy S. Kahan and Michael K. Kahan (each, a "Reporting Person" and collectively, the "Reporting Persons"). North Peak Management is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, each of Fund I, Fund II, Alpha Fund and Ultra Fund. North Peak Management is also an investment adviser to a separately managed account of an advisory client and may be deemed to beneficially own securities directly in such separately managed account, but North Peak Management does not have any voting authority with respect to any securities in such separately managed account. North Peak GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, each of Fund I, Fund II, Alpha Fund and Ultra Fund. Messrs. Kahan are the co-managers of, and each may be deemed to indirectly beneficially own securities beneficially owned by, each of North Peak Management and North Peak GP. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock held directly by the other Reporting Persons. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o North Peak Capital Management, LLC, 405 Lexington Avenue, Suite 5001, New York, NY 10174.
    (c)Citizenship:

    See Item 4 on the cover page(s) hereto.
    (d)Title of class of securities:

    Common stock, par value $0.01
    (e)CUSIP No.:

    00857U107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Item 9 on the cover page(s) hereto.
    (b)Percent of class:

    See Item 11 on the cover page(s) hereto.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 on the cover page(s) hereto.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 on the cover page(s) hereto.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 on the cover page(s) hereto.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 on the cover page(s) hereto.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    North Peak Capital Management, LLC
     
    Signature:/s/ Jeremy Kahan
    Name/Title:Jeremy Kahan/Managing Member
    Date:08/29/2025
     
    North Peak Capital GP, LLC
     
    Signature:/s/ Jeremy Kahan
    Name/Title:Jeremy Kahan/Manager
    Date:08/29/2025
     
    North Peak Capital Partners, LP
     
    Signature:/s/ Jeremy Kahan
    Name/Title:Jeremy Kahan/Manager
    Date:08/29/2025
     
    North Peak Capital Partners II, LP
     
    Signature:/s/ Jeremy Kahan
    Name/Title:Jeremy Kahan/Manager
    Date:08/29/2025
     
    North Peak Capital Alpha Fund, LP
     
    Signature:/s/ Jeremy Kahan
    Name/Title:Jeremy Kahan/Manager
    Date:08/29/2025
     
    North Peak Capital Ultra Fund, LP
     
    Signature:/s/ Jeremy Kahan
    Name/Title:Jeremy Kahan/Manager
    Date:08/29/2025
     
    Michael Kevin Kahan
     
    Signature:/s/ Michael Kahan
    Name/Title:MICHAEL KAHAN
    Date:08/29/2025
     
    Jeremy Steven Kahan
     
    Signature:/s/ Jeremy Kahan
    Name/Title:JEREMY KAHAN
    Date:08/29/2025
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement (filed herewith)

    Get the next $AGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGL

    DatePrice TargetRatingAnalyst
    8/20/2025$1.40Outperform → Mkt Perform
    Bernstein
    8/6/2025$1.00Buy → Neutral
    Citigroup
    4/25/2025$5.00Neutral → Buy
    Citigroup
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    1/10/2025Hold
    Needham
    12/16/2024Neutral
    Macquarie
    12/11/2024$2.50Mkt Perform
    Bernstein
    More analyst ratings

    $AGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    agilon health Sets Date to Report Third Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 291396. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be availabl

    10/6/25 4:12:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health to Participate in the 2025 Jefferies Healthcare Services Conference

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the 2025 Jefferies Healthcare Services Conference on Tuesday, September 30 at 8:45am ET. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering physici

    9/16/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

    SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

    9/5/25 5:41:23 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SCHEDULE 13G filed by agilon health inc.

    SCHEDULE 13G - agilon health, inc. (0001831097) (Subject)

    8/29/25 11:00:27 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

    SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

    8/13/25 12:56:59 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agilon Health downgraded by Bernstein with a new price target

    Bernstein downgraded Agilon Health from Outperform to Mkt Perform and set a new price target of $1.40

    8/20/25 8:21:47 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health downgraded by Citigroup with a new price target

    Citigroup downgraded Agilon Health from Buy to Neutral and set a new price target of $1.00

    8/6/25 7:57:52 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health upgraded by Citigroup with a new price target

    Citigroup upgraded Agilon Health from Neutral to Buy and set a new price target of $5.00

    4/25/25 8:23:09 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

    4/A - agilon health, inc. (0001831097) (Issuer)

    4/3/25 7:40:25 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/18/25 6:42:37 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Markets Officer Shaker Benjamin bought 11,786 shares and covered exercise/tax liability with 4,143 shares, increasing direct ownership by 2% to 457,058 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/18/25 6:41:48 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 406 shares, decreasing direct ownership by 0.35% to 114,752 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    8/19/25 5:39:24 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Legal Officer Zamore Denise covered exercise/tax liability with 915 shares, decreasing direct ownership by 0.21% to 443,125 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    8/5/25 5:10:48 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 46,099 shares, decreasing direct ownership by 4% to 1,075,122 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    7/3/25 4:08:23 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Financials

    Live finance-specific insights

    View All

    agilon health Sets Date to Report Third Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 291396. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be availabl

    10/6/25 4:12:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report Second Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the second quarter 2025 after the market closes on Tuesday, August 5, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 938716. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of t

    7/22/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report First Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

    3/25/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Leadership Updates

    Live Leadership Updates

    View All

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

    Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d

    7/10/24 8:00:00 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Names Jeff Schwaneke New Chief Financial Officer

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,

    6/5/24 8:00:00 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/13/24 12:49:26 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/8/24 10:52:39 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/6/24 4:47:14 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care